weight plateau on tirzepatide Overcoming a Loss with GLP-1 Medications Surmount/72 Week Plateau Question :

ADEs: adverse drug events cAMP: cyclic adenosine monophosphate GIP: glucose-dependent insulinotropic polypeptide GIPR: glucose-dependent insulinotropic polypeptid receptor GLP-1: glucagon-like peptide-1 GLP-1R: glucagon-like peptide-1 receptor GLP-1RAs: glucagon-like peptide-1 receptor agonists GPCR: G-protein-coupled receptor IR: insulin resistance MALO: major adverse liver outcomes MASH: metabolic dysfunction-associated steatohepatitis MASLD: metabolic dysfunction-associated steatotic liver disease PKA: protein kinase A RCTs: randomized controlled trials T2DM: type 2 diabetes mellitus Authors used RWTHgpt software in order to improve the readability and language of the manuscript

Ma RC, Xu G

It is a one-time shift due to the evacuation of waste and fluid

Six WT mice and six GLP-1R KO mice had cAMP measured